Aged female mice given semaglutide late in life lived measurably longer than untreated animals, and the drug matched or exceeded the benefits of eating less on tests of memory, movement, and blood sugar control. Median lifespan rose from 742 days to 834 days, about 12 percent, according to the study published in Nature by a team at the University of California, Berkeley.
The result is already circulating online as evidence that Ozempic and Wegovy extend human life. It does not show that, not yet, and not in people. The animals were a single inbred strain of laboratory mouse, all female, treated beginning at 20 months of age. No human trial has tested whether semaglutide slows aging, and no regulator has approved a GLP-1 medicine for that purpose.
The distinction carries real consequences. Millions of Americans already take GLP-1 drugs for diabetes, obesity, cardiovascular risk, kidney disease or fatty liver disease, and a longevity narrative can push people toward higher doses, unapproved sellers or off-label use that no evidence supports.
Inside the Berkeley Lifespan Experiment
Researchers led by Danica Chen, a professor of metabolic biology and nutrition at UC Berkeley, gave semaglutide to 20-month-old female mice, one group for three months and another for the rest of their lives. Yufan Feng, a postdoctoral researcher in Chen's lab, was the lead author.
The National Institutes of Health, which funded the work, said treated animals showed improved muscle and cognitive function, and that gene expression analysis found reduced inflammation and less loss of regenerative capacity.
Because semaglutide suppresses appetite, the team had to rule out the simplest explanation. Over five months, researchers ran a head-to-head comparison against mice placed on a matched 24 percent calorie restriction, the best-established way to extend lifespan in laboratory animals. According to UC Berkeley's account of the work, treated mice showed more exploratory behavior, better spatial memory and better blood-sugar maintenance than the calorie-restricted group, and their metabolic rate was largely unchanged while the calorie-restricted animals slowed down.
Chen said those differences point to the possibility that GLP-1 drugs tap into "a biological pathway independent of calorie restriction."
Reading the Result Without Overreading It
This was an animal study, not a clinical trial, and the limits are specific. Every animal was female, and sex differences are common in aging research, so the finding cannot be assumed to apply to males. All were C57BL/6 mice, a single genetic background, so the effect has not been shown across the genetically diverse populations that better approximate people.
The NIH was explicit that while the findings may guide future research, they do not imply that similar results could be achieved immediately in humans. The authors say testing longevity in people would require long-term clinical studies in older populations.
One disclosure belongs with the science. The Regents of the University of California have filed a patent application covering GLP-1 receptor agonists for healthy aging.
What the study does offer is a plausible mechanism. GLP-1 medicines already show benefits beyond weight and blood sugar, and researchers have struggled to explain why one drug class helps so many organ systems. As Chemical & Engineering News reported, longevity researchers have spent years hunting for calorie-restriction mimetics that people can tolerate, because crash diets are hard to sustain. If GLP-1 receptor activation partly mimics calorie restriction, that supplies a single explanation for a scattered set of effects.
Nothing Here Changes Prescriptions Today
Current medical guidance has not changed. Semaglutide remains approved for specific conditions, and this paper does not create a longevity indication or a reason to take the drug without a diagnosis. No one should start, adjust, or stop a prescribed medication without speaking to a qualified clinician.
The people most likely to be harmed by a misreading are older adults at risk of unintended weight and muscle loss, patients who cannot tolerate gastrointestinal side effects, and anyone buying compounded or unverified versions online in pursuit of anti-aging effects. Coverage varies widely by plan, and prior authorization is common, so patients facing denials can ask their prescriber about appeals, medical necessity documentation or manufacturer assistance programs.
The Longevity Questions Trials Have Not Answered
The next steps are human data. No dedicated trial of semaglutide for healthy aging has been reported, and such trials take years because the outcome is survival. Worth watching: results in male animals, results in genetically diverse mouse populations, and any regulatory filing that names aging as an indication.
Until then, the summary is narrow. A widely used drug extended life in aged female mice; the effect appears to go beyond appetite suppression, and whether any of it applies to people is unknown.
Key Questions Answered
What did the study find? Female mice treated with semaglutide from 20 months of age had a median lifespan of 834 days, compared with 742 days in untreated controls, and did better on tests of muscle function, memory, and glucose control.
Does this mean Ozempic or Wegovy extends human life? No. This was a mouse study. No human trial has tested semaglutide for longevity, and no regulator has approved a GLP-1 drug for slowing aging.
Why does it matter that all the mice were female? Aging interventions often work differently by sex, so a female-only result cannot be assumed to apply to males. The animals were also one inbred strain, which further limits generalization.
What is a calorie-restriction mimetic? A drug that reproduces some biological effects of eating less without a restricted diet. This study compared semaglutide against a matched 24 percent calorie restriction and found overlapping benefits.
Should anyone change their medication because of this? No. Guidance has not changed. Do not start, stop, or adjust a prescription without speaking to a qualified clinician.
